Free website hits

Over a recent seven-year period, Medicare Part D spending on inhalers used to control respiratory problems increased $2 billion, or a whopping 44%, as more people used the devices, according to a new study. However, a lack of lower-cost generic options has also allowed prices to remain high.

From 2012 to 2018, the federal health care program spent $39.7 billion — adjusted for inflation and discounts — on inhalers to help plan beneficiaries combat asthma and chronic obstructive pulmonary disease, or COPD. By 2018, the nine different classes of inhalers accounted for nearly 5% of roughly $120 billion in overall spending by the Part D plan after rebates and other discounts.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Source: STATNEWS.COM

Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]